Literature DB >> 18344046

Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?

Christoph Hiemke1.   

Abstract

To produce its characteristic effects, a drug must be present in appropriate concentrations at its sites of action. The latter is not only a function of the dose administered, but also of the extent and rate of drug absorption, distribution, tissue binding, biotransformation, and excretion, which can vary markedly between individual patients due to differences in gender, age, morbidity, smoking or eating habits, differential expression of drug metabolising enzymes or drug transporters or other factors. Therefore drug concentrations in blood resulting after a given dose differ by tenfold or more between individual patients. For psychoactive drugs, animal studies have shown that plasma concentrations of psychotropic drugs correlate well with concentrations in the target organ, the brain. In the brain of patients treated with antipsychotic or antidepressant drugs clear-cut relationships were found between plasma concentrations of the drug and occupancy of dopamine receptors or serotonin uptake sites by positron emission tomography (PET). Monitoring concentrations of psychoactive drugs in plasma of patients, so called therapeutic drug monitoring (TDM), is therefore useful to adjust dosages for optimal "receptor" blockade. TDM is well established for mood stabilizers and anticonvulsant drugs. For other neuropsychiatric drugs, however, "routine" TDM is rare. Optimal target concentrations are unclear for many drugs, and the number of laboratories that use reliable methods to measure the low concentrations of the drugs within a single day is quite limited. Moreover, the use of TDM in practice is far from optimal. The TDM group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP see http://www.agnp.de/) has published literature-based guidelines for optimal use of TDM in psychiatry. TDM can be most informative to solve problems underlying the treatment of an individual patient. It can be clarified if suggested non-compliance or insufficient response in spite of recommended doses is due to rapid metabolism of the drug. Moreover, many drug interactions have been detected by using TDM. In conclusion, TDM is a reliable tool to optimise psychopharmacotherapy. When used adequately it is helpful for many psychiatric patients and in many situations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344046     DOI: 10.1007/s00406-007-1005-y

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  55 in total

1.  Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography.

Authors:  H Weigmann; S Härtter; S Maehrlein; W Kiefer; G Krämer; G Dannhardt; C Hiemke
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-08-05

Review 2.  The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development.

Authors:  Peter S Talbot; Marc Laruelle
Journal:  Eur Neuropsychopharmacol       Date:  2002-12       Impact factor: 4.600

3.  Early prediction of antipsychotic response in schizophrenia.

Authors:  Christoph U Correll; Anil K Malhotra; Saurabh Kaushik; Marjorie McMeniman; John M Kane
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

Review 4.  Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau".

Authors:  Finn Bengtsson
Journal:  Ther Drug Monit       Date:  2004-04       Impact factor: 3.681

5.  Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach.

Authors:  H Kirchherr; W N Kühn-Velten
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-06-23       Impact factor: 3.205

6.  Use of plasma level monitoring of antidepressants in clinical practice. Towards an analysis of clinical utility.

Authors:  F Vuille; M Amey; P Baumann
Journal:  Pharmacopsychiatry       Date:  1991-11       Impact factor: 5.788

Review 7.  Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

Authors:  R J Baldessarini; B M Cohen; M H Teicher
Journal:  Arch Gen Psychiatry       Date:  1988-01

8.  Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats.

Authors:  C. Lindsay DeVane; David W. Boulton; Lisa F. Miller; Ronald L. Miller
Journal:  Int J Neuropsychopharmacol       Date:  1999-03       Impact factor: 5.176

9.  Therapeutic drug monitoring of 13 antidepressant and five neuroleptic drugs in serum with liquid chromatography-electrospray ionization mass spectrometry.

Authors:  Ursula Gutteck; Katharina M Rentsch
Journal:  Clin Chem Lab Med       Date:  2003-12       Impact factor: 3.694

Review 10.  An economic evaluation of schizophrenia--1991.

Authors:  R J Wyatt; I Henter; M C Leary; E Taylor
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1995-08       Impact factor: 4.328

View more
  9 in total

1.  The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.

Authors:  Brandon Mansoor; Manivel Rengasamy; Robert Hilton; Giovanna Porta; Jiayan He; Anthony Spirito; Graham J Emslie; Taryn L Mayes; Gregory Clarke; Karen Dineen Wagner; Wael Shamseddeen; Boris Birmaher; Neal Ryan; David Brent
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-09-11       Impact factor: 2.576

2.  Lack of relationship between plasma levels of escitalopram and QTc-interval length.

Authors:  Mar Carceller-Sindreu; Javier de Diego-Adeliño; Maria J Portella; Xavier Garcia-Moll; Maria Figueras; Aina Fernandez-Vidal; Josep M Queraltó; Dolors Puigdemont; Enric Álvarez
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-01-23       Impact factor: 5.270

3.  Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study.

Authors:  Dara J Sakolsky; James M Perel; Graham J Emslie; Gregory N Clarke; Karen Dineen Wagner; Benedetto Vitiello; Martin B Keller; Boris Birmaher; Joan Rosenbaum Asarnow; Neal D Ryan; James T McCracken; Michael J Strober; Satish Iyengar; Giovanna Porta; David A Brent
Journal:  J Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.153

4.  Neuroimaging in psychiatry: from bench to bedside.

Authors:  David E J Linden; Andreas J Fallgatter
Journal:  Front Hum Neurosci       Date:  2009-12-23       Impact factor: 3.169

Review 5.  The role of molecular imaging in the diagnosis and management of neuropsychiatric disorders.

Authors:  Lie-Hang Shen; Yu-Chin Tseng; Mei-Hsiu Liao; Ying-Kai Fu
Journal:  J Biomed Biotechnol       Date:  2011-03-22

Review 6.  Biomarkers in development of psychotropic drugs.

Authors:  K Wiedemann
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

Review 7.  Role of Hybrid Brain Imaging in Neuropsychiatric Disorders.

Authors:  Amer M Burhan; Nicole M Marlatt; Lena Palaniyappan; Udunna C Anazodo; Frank S Prato
Journal:  Diagnostics (Basel)       Date:  2015-12-04

Review 8.  Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.

Authors:  Lie-Hang Shen; Mei-Hsiu Liao; Yu-Chin Tseng
Journal:  J Biomed Biotechnol       Date:  2012-04-10

9.  Serum N-Desmethylcitalopram Concentrations are Associated with the Clinical Response to Citalopram of Patients with Major Depression.

Authors:  Gul Ozbey; Berna Yucel; Nurdan Eren Bodur; Serap Erdogan Taycan; Tayyibe Arslan; Nazan Cerit; Nevzat Yuksel; Ismail Cuneyt Guzey; Canan Uluoglu
Journal:  Psychiatry Investig       Date:  2018-02-22       Impact factor: 2.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.